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Institut d’Investigació Biomèdica de Bellvitge, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, SpainAbstractAlthough bloodstream infection (BSI) is a major cause of mortality after solid organ transplantation, information regarding its prognostic
factors is scarce. To identify risk factors for 30-day mortality in solid organ transplant (SOT) recipients with BSI, we prospectively
recorded all episodes of BSI occurring in adult SOT recipients from January 2007 to October 2014 at a university hospital. We identiﬁed
361 consecutive episodes of BSI involving 246 patients. The 30-day case-fatality rate from the onset of BSI was 11.4%. Factors
independently associated with 30-day mortality in a logistic regression analysis were shock at presentation (OR 13.658; 95% CI
5.985–31.168), acute graft rejection in the previous 6 months (OR 3.681; 95% CI 1.059–12.795), and a platelet count of <50 000 × 109/
L (OR 3.070; 95% CI 1.173–8.038). Kidney recipients were the patients with the best prognosis (OR 0.375; 95% CI 0.156–0.900). Our
ﬁndings may help to identify SOT recipients with BSI who are at the highest risk of death.
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E-mail: jcarratala@ub.eduIntroductionThe number of cases of solid organ transplantation has risen
dramatically in recent years, and, currently, solid organ trans-
plantation extends the life-expectancy of >25 000 patients with
end-stage organ diseases each year in the USA [1]. Neverthe-
less, the risk of infection after solid organ transplantation re-
mains high, owing to the immunosuppressive treatment
required to avoid graft rejection. Despite changes in immuno-
suppressive regimens and routine prophylaxis for infection,
infectious diseases continue to constitute a major complication
and the leading cause of morbidity and mortality among theseMicrobiol Infect 2015; 21: 1104.e9–1104.e14
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.07.021patients, especially in the ﬁrst month post-transplantation
[2–4].
The management of bacterial infections in solid organ
transplant (SOT) recipients is one of the most challenging
clinical issues today [5]. In particular, bloodstream infection
(BSI) is the most frequent life-threatening infectious complica-
tion after SOT [3,6]. Its incidence in the ﬁrst 30 days ranges
from 7.4% to 14%, depending on the type of transplant [3].
Signiﬁcantly, recent studies have reported a shift in the distri-
bution of the aetiology of BSI towards Gram-negative bacteria,
especially multidrug-resistant (MDR) strains, as the predomi-
nant pathogens [6–8]. There has also been a sharp increase in
the number of nosocomial-acquired infections, exposing SOT
recipients to an increased risk of serious infections due to MDR
pathogens, which are particularly difﬁcult to treat [3]. Infections
due to MDR organisms have also been associated with poor
outcomes in some studies [4,8,9].
The management and prevention of bacterial infections in
SOT recipients has become a key issue in modernious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Oriol et al. Mortality in SOT recipients with BSI 1104.e10transplantation [2]. The identiﬁcation of prognostic factors
associated with mortality that are amenable to medical inter-
vention may well help to improve the outcomes of SOT re-
cipients. However, current information about risk factors for
mortality among these patients is scarce, and mainly derives
from retrospective studies focusing on the mortality rates due
to individual microorganisms.
The aim of this study was to determine the factors inﬂu-
encing mortality in a recent, large series of prospectively
documented BSIs occurring in adult SOT recipients.Materials and methodsSetting and study population
We conducted a prospective observational study at a tertiary
university referral hospital in Barcelona, Spain, with an active
transplantation programme (annual average of 104 kidney
transplants, 50 liver transplants, and 15 heart transplants). From
1 January 2007 to 31 October 2014, all episodes of BSI
occurring in hospitalized adult SOT recipients were included.
Data regarding baseline characteristics, including immunosup-
pressive treatment, occurrence of acute allograft rejection and
opportunistic infections, clinical features, microbiological
studies, and outcomes, were carefully recorded in a speciﬁc
database. For the purposes of this study, patients were divided
into two groups according to their ﬁnal outcome: survivors and
non-survivors at 30 days from the onset of BSI. The two groups
were compared to identify risk factors inﬂuencing mortality.
The study was approved by the ethics committee of our
institution.
At our hospital, the microbiology laboratory reports all pos-
itive results of blood cultures to the infectious disease team on a
daily basis. All patients with BSI are visited by an infectious dis-
ease physician and followed up. Changes in antimicrobial treat-
ment and general management are discussed when necessary.
Deﬁnitions
In accordance with the current standard deﬁnition, multidrug
resistance was deﬁned as acquired non-susceptibility to at least
one agent in three or more antimicrobial categories [10]. BSI
was considered to be nosocomial-acquired or community-
acquired according to the criteria described previously [11].
Graft dysfunction before the onset of BSI was deﬁned as fol-
lows: serum creatinine level of >1.5 mg/dL in kidney recipients;
recurrence of hepatitis C virus, ischaemic cholangitis or
cirrhosis in liver recipients; and history of heart failure in heart
recipients. The BSI source was determined on the basis of
clinical criteria, and isolation of any organism from a clinically
signiﬁcant site of infection matched with that obtained in bloodClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeccultures on the basis of the species identiﬁcation and antibiotic
susceptibility results. Catheter-related BSI was documented
when the blood isolate was cultured from the catheter tip
(>103 CFUs/mL). As the depth of infection was often difﬁcult to
determine, we combined surgical wound infections and
abdominal organ/space infections into a single infectious source
[12]. BSI was considered to be from a primary or unknown
source in patients in whom no other BSI sites were identiﬁed.
Prior antibiotic therapy was deﬁned as the receipt of any
systemic antibiotic for 48 h in the previous month. Empirical
antibiotic therapy was considered to be inadequate or inap-
propriate if the treatment regimen did not include at least one
antibiotic active in vitro against the infecting microorganism.
Sepsis is deﬁned as the presence (probable or documented)
of infection together with systemic manifestations of infection.
Septic shock was deﬁned as sepsis-induced hypotension per-
sisting despite adequate ﬂuid resuscitation, according to the
International Guidelines of the Surviving Sepsis Campaign [13].
Acute allograft rejection was considered to be present when
proven by biopsy, and 30-day mortality was deﬁned as death
from any cause within the ﬁrst 30 days of the onset of BSI.
Antimicrobial prophylaxis
SOT patients received perioperative antibacterial prophylaxis
for up to 48 h after transplantation. Speciﬁcally, kidney re-
cipients received intravenous amoxycillin–clavulanate, and
heart and liver recipients received intravenous vancomycin or
teicoplanin plus aztreonam. Prophylaxis to prevent Pneumocystis
jiroveccii infection with trimethoprim–sulphamethoxazole (a
double-strength tablet taken once three times a week) was
given in the ﬁrst 6 months after transplantation. We used a
prophylactic approach for those patients at high risk of cyto-
megalovirus disease [D+/R– patients, and patients who received
antithymocyte globulin (ATG)]. In the other cases, we used a
pre-emptive therapy approach [14]. We used Candida pro-
phylaxis in high-risk liver transplant recipients. The antifungal
administered was either ﬂuconazole or an echinocandin,
depending on the risk of drug interactions and toxicity. In heart
recipients at high risk of invasive aspergillosis, we used intra-
venous amphotericin B (intravenous or nebulized) or an echi-
nocandin [15].
Microbiological studies
Blood samples were processed with the BACTEC 9240 method
(Becton-Dickinson Microbiology Systems, Sparks, MD, USA).
The inoculated bottles were incubated for 5 days at 35ºC
before being discharged. Microbial identiﬁcation was performed
with commercially available panels (MicroScan (Siemens
Healthcare Diagnosis Inc; West Sacramento, CA, USA) or Vitek
(bioMérieux SA; Marcy-L’Etoile, France)), with standardtious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1104.e9–1104.e14
TABLE 1. Clinical characteristics of solid organ transplant
recipients with bloodstream infection (BSI) according to
30-day mortality
Variables
Survivors
(N [ 320)
Non-
survivors
(N [ 41) p
Male sex, n (%) 228 (71.3) 31 (75.6) 0.689
Age (years), median (IQR) 63 (56–67) 60 (53–65) 0.194
Underlying diseases, n (%) 268 (83.8) 32 (78.0) 0.487
Renal impairmenta 28 (8.8) 7 (17.1) 0.157
Diabetes mellitus 80 (25.2) 8 (19.5) 0.564
Heart disease 61 (19.1) 7 (17.1) 0.925
COPD 23 (7.2) 5 (12.2) 0.413
Haematological disorders 9 (2.8) 4 (9.8) 0.072
Solid tumour 15 (4.7) 1 (2.4) 0.798
Other 106 (33) 10 (24.4) 0.342
Type of transplant, n (%)
Kidney 179 (55.9) 9 (22.0) <0.001
Liver 95 (29.7) 22 (53.7) 0.004
Heart 43 (13.4) 8 (19.5) 0.416
1104.e11 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIbiochemical and/or enzymatic tests, or with matrix-assisted
laser desorption ionization time-of-ﬂight mass spectrometry
(Bruker Daltonics; Bremen, Germany). CLSI criteria were used
to deﬁne susceptibility or resistance to antimicrobial agents.
Antibiotic susceptibility was tested with the microdilution
method, following CLSI guidelines. The screening of MDR
phenotypes, including methicillin-resistant Staphylococcus aureus
ampicillin-resistant enterococci, extended-spectrum β-lacta-
mase producers, and carbapenemase producers, was per-
formed according to CLSI recommendations.
Statistical analysis
To compare patients for 30-day mortality, we used the chi-
square test with continuity correction for categorical vari-
ables. Continuous data are presented as median (interquartile
range (IQR)), and were analysed with the Mann–Whitney U-
test. Multivariate conditional regression analysis of factors
potentially associated with mortality was performed, including
all statistically signiﬁcant variables in the univariate analysis, sex
and age, and all clinically important variables regardless of
whether or not they were statistically signiﬁcant. ORs and 95%
CIs were calculated. The analysis was performed with the
stepwise logistic regression model of SPSS version 18.0 (SPSS,
Chicago, IL, USA). The survival curve was plotted with the
Kaplan–Meier method. All statistical tests were two-tailed, and
the threshold of statistical signiﬁcance was p < 0.05.
Multi-organ 3 (0.9) 1 (2.4) 0.942
Prior transplant, n (%) 20 (6.3) 2 (4.9) 1
Immunosuppressive regimens, n (%)
Prednisone 241 (75.3) 31 (75.6) 1
Tacrolimus 19 (5.9) 6 (14.6) 0.082Results
Cyclosporine A 23 (7.2) 4 (9.8) 0.785
Mycophenolate mofetil 13 (4.1) 4 (9.8) 0.219
mTOR inhibitors 13 (4.1) 2 (4.9) 1
Tacrolimus + mycophenolate mofetil 159 (49.7) 14 (34.1) 0.087
Cyclosporine A + mycophenolate
mofetil
68 (21.3) 7 (17.1) 0.677
mTOR inhibitors + mycophenolate
mofetil
30 (9.4) 0 0.081
Tacrolimus + mTOR inhibitors 5 (1.6) 1 (2.4) 1
Lymphocyte-depleting antibody at
transplant
141 (44.1) 22 (53.7) 0.319
OKT3/ATG (6 months) 24 (7.5) 2 (4.9) 0.771
Receipt of more than one pulse of
1 g of intravenous methylprednisolone
(6 months)
35 (10.9) 6 (15.0) 0.618
Graft dysfunction before the onset of
BSIb, n (%)
58 (18.1) 18 (43.9) <0.001
Nosocomial acquisition, n (%) 183 (57.2) 32 (78.0) 0.017
ICU stay at the onset of BSI, n (%) 46 (14.4) 17 (41.5) <0.001
Acute allograft rejection within the
preceding 6 months, n (%)
18 (5.6) 7 (17.1) 0.017
Prior antibiotic therapyc, n (%) 209 (65.7) 32 (78.0) 0.160
TMP–SMZ prophylaxis, n (%) 75 (23.4) 14 (34.1) 0.192
Use of urinary catheter, n (%) 107 (33.4) 23 (56.1) 0.008
Use of venous catheter, n (%) 153 (47.8) 30 (73.2) 0.004
Median days from transplantation (IQR) 222 (31–2187) 263 (41–1580) 0.952
30 days from transplantation, n (%) 79 (24.7) 4 (9.8) 0.052
90 days from transplantation, n (%) 124 (38.8) 15 (36.6) 0.922
ATG, antithymocyte globulin; COPD, chronic obstructive pulmonary disease; ICU,
intensive-care unit; IQR, interquartile range; mTOR, mammalian target of
rapamycin; TMP–SMZ, trimethoprim–sulphamethoxazole.
aRenal impairment was deﬁned as a serum creatinine level of >1.5 mg/dL.
bGraft dysfunction before the onset of BSI was deﬁned as follows: serum creatinine
level of >1.5 mg/dL in kidney recipients; recurrence of hepatitis C virus, ischaemic
cholangitis or cirrhosis in liver recipients; history of heart failure in heart recipients.
cPrior antibiotic therapy was deﬁned as the receipt of any systemic antibiotic in the
preceding month.During the study period, 361 consecutive episodes of BSI were
prospectively documented among 246 SOT recipients. Sixty-
nine patients had more than one episode of BSI. The 30-day
case-fatality rate was 11.4%. Sixty-one per cent of deaths (25/
41) occurred within the ﬁrst 7 days.
The median age of the subjects was 63 years (IQR 53–67
years). Seventy-two per cent of the episodes occurred in men,
60% were hospital-acquired, and 17% occurred in patients
admitted to the intensive-care unit (ICU). Sixty-nine patients
had more than one episode of BSI. The median time from
transplantation to the onset of BSI was 222 days (IQR 31–2075
days). The most common source of infection was the urinary
tract (37%), followed by the abdomen (25%) and catheters
(16%). In 12% of the episodes, the source of infection was
considered to be unknown. Causes of death of SOT recipients
with BSI were shock/multiple organ failure (32 of 41 patients),
respiratory failure (ﬁve of 41 patients), and acute hepatic
insufﬁciency (four of 41 patients).
Table 1 shows the baseline characteristics of SOT recipients
with BSI according to 30-day mortality. In the univariateClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectanalysis, liver recipients were more likely to have suffered a
poor outcome, whereas kidney transplantation was associated
with a lower mortality rate at 30 days. Table 1 also shows that
nosocomial acquisition, admission to the ICU before the onset
of BSI, the presence of acute graft rejection in the previous 6
months and the use of urinary and venous catheters were more
frequent among non-survivors.
Patients with acute rejection within 6 months before the
onset of BSI had only one episode of rejection. In the survivors
group, six of seven patients showed a moderate degree ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1104.e9–1104.e14
TABLE 3. Causative pathogens isolated in each episode of
bloodstream infection (BSI) according to 30-day mortality
Causative organisms
Survivors
(N [ 320)
Non-survivors
(N [ 41) p
Monomicrobial BSI, n (%) 282 (88.1) 35 (85.4) 0.612
Gram-positive bacteria 69 (24.5) 13 (37.1) 0.106
CNS 18 (6.4) 5 (14.3) 0.155
MSSA 15 (5.3) 0 0.388
MRSA 3 (1.1) 1 (2.9) 0.375
Enterococcus faecalis 12 (4.3) 2 (5.7) 0.659
Enterococcus faecium 8 (2.8) 3 (8.6) 0.110
Streptococcus pneumoniae 7 (2.5) 1 (2.9) 1
Listeria monocytogenes 3 (1.1) 0 1
Other 3 (1.1) 1 (2.9) 0.375
GNB 209 (74.1) 19 (54.3) 0.014
Escherichia coli 99 (35.1) 6 (17.1) 0.033
Klebsiella pneumoniae 47 (16.7) 1 (2.9) 0.057
Enterobacter species 13 (4.6) 0 0.375
Serratia marcescens 3 (1.1) 0 1
Morganella morganii 3 (1.1) 0 1
Salmonella enteritidis 2 (0.7) 0 1
Pseudomonas aeruginosa 27 (9.6) 8 (22.9) 0.039
Acinetobacter baumanii 3 (1.1) 1 (2.9) 0.375
Stenotrophomonas maltophilia 0 1 (2.9) 0.110
Other GNB 5 (1.8) 1 (2.9) 0.507
Bacteroides fragilis 3 (1.1) 1 (2.9) 0.445
Other 3 (1.1) 0 1
MDR Gram-negative bacilli 67 (23.8) 9 (25.7) 0.798
ESBL-producing Enterobacteriaceae 32 (11.3) 2 (5.7) 0.584
Carbapenem-resistant GNB 25 (8.9) 8 (22.9) 0.018
Yeast 4 (1.4) 3 (8.6) 0.032
Candida albicans 4 (1.4) 0 1
Candida non-albicans 0 3 (8.6) <0.001
Polymicrobial, n (%) 38 (11.9) 6 (14.6) 0.612
CNS, coagulase-negative staphylococci; ESBL, extended-spectrum β-lactamase;
GNB, Gram-negative bacilli; MDR, multidrug-resistant; MRSA, methicillin-resistant
Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.
CMI Oriol et al. Mortality in SOT recipients with BSI 1104.e12rejection according to histopathology. The other one showed a
severe degree of rejection. All of these patients were treated
with a bolus of steroids. In the non-survivors group, 13 of 15
patients showed a moderate degree of rejection, one patient
showed borderline rejection, and one patient showed a severe
degree of rejection. Seven of the patients had been treated with
a bolus of steroids, three had been treated with a bolus of
steroids plus ATG, three had been treated only with ATG, and
one had been treated with plasmapheresis and intravenous
immunoglobulins; the patient with borderline rejection had
been treated with increased doses of the immunosuppressive
drugs.
Table 2 shows the clinical and laboratory ﬁndings at the
onset of BSI according to 30-day mortality. Shock at presen-
tation, renal impairment and concomitant infection due to
cytomegalovirus were more frequent among non-survivors.
Regarding the laboratory ﬁndings, non-survivors had lower
levels of serum albumin and lower blood counts of leukocytes,
neutrophils, lymphocytes and platelets than survivors.
Table 3 shows the causative pathogens isolated in each episode
of BSI according to 30-day mortality. Seventy-two per cent of
monomicrobial BSIs were due to Gram-negative bacilli (GNB).
GNB showed a high rate of resistance tomajor antibiotics (33.3%
of them were MDR and 14.5% were carbapenem-resistant).
Carbapenem resistance was more frequent among non-
survivors, accounting for 42% of the isolates. No episodes with
vancomycin-resistant Enterococcus faecium were found. The fre-
quency of MRSA bacteraemia was also low.
After application of a backward stepwise logistic regression
model (Table 4), septic shock at presentation (OR 13.658; 95%TABLE 2. Clinical and laboratory ﬁndings at the onset of
bloodstream infection according to 30-day mortality
Variables
Survivors
(N [ 320)
Non-survivors
(N [ 41) p
Clinical presentation, n (%)
Septic shock at presentationa 34 (10.6) 29 (70.7) <0.001
Renal impairmentb 111 (34.7) 29 (70.7) <0.001
ICU admission 68 (21.3) 29 (70.7) <0.001
Inadequate empirical
antibiotic therapyc
88 (28.1) 14 (36.8) 0.353
Concomitant CMV 32 (10.0) 9 (22.0) 0.045
Laboratory ﬁndings, n (%)
Platelet count of <50 000/mm3 17 (5.3) 15 (36.6) <0.001
Lymphocyte count of <500/mm3 130 (40.6) 24 (58.5) 0.044
Neutrophil count of <1000/mm3 10 (3.1) 5 (12.2) 0.020
White blood cell
count of <5000/mm3
67 (20.9) 17 (41.5) 0.006
Hypoalbuminaemiad 175 (54.7) 34 (82.9) 0.001
CMV, cytomegalovirus; ICU, intensive-care unit.
aSeptic shock was deﬁned as sepsis-induced hypotension persisting despite adequate
ﬂuid resuscitation.
bRenal impairment was deﬁned as a serum creatinine level of >1.5 mg/dL.
cEmpirical antibiotic therapy was considered to be inadequate if the treatment
regimen did not include at least one antibiotic active in vitro against the infecting
microorganism.
dHypoalbuminaemia was deﬁned as a serum albumin level of < 3g/L.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfecCI 5.985–31.168), the presence of acute graft rejection in the
previous 6 months (OR 3.681; 95% CI 1.059–12.795) and a
platelet count of <50 000 × 109/L (OR 3.070; 95% CI
1.173–8.038) were found to be risk factors for 30-day mor-
tality of SOT recipients with BSI. Kidney transplantation (OR
0.375; 95% CI 0.156–0.900) was associated with the best
prognosis.DiscussionSeptic shock at presentation, the presence of acute graft
rejection in the previous 6 months and a platelet count of
<50 000 × 109/L were the only factors that were independentlyTABLE 4. Independent risk factors for 30-day mortality in
solid organ transplant recipients with bloodstream infection
Variables OR (95% CI) p
Septic shock at presentationa 13.658 (5.985–31.168) <0.001
Acute graft rejection within the
preceding 6 months
3.681 (1.059–12.795) 0.040
Platelet count of <50 000/mm3 3.070 (1.173–8.038) 0.022
Kidney recipients 0.375 (0.156–0.900) 0.028
aSeptic shock was deﬁned as sepsis-induced hypotension persisting despite adequate
ﬂuid resuscitation.
tious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1104.e9–1104.e14
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BSI. Kidney transplantation was related to better prognosis.
Septic shock is the most severe complication in the context
of BSI in SOT recipients and in the general population [4,16].
Improving the management of septic shock remains a great
challenge. Numerous therapeutic strategies aimed at reducing
mortality in this group of critically ill patients, including thera-
pies to modulate and downregulate the complex network of
sepsis-induced inﬂammatory and coagulopathy processes, have
been studied. However, most studies have not shown signiﬁ-
cant reductions in mortality [17,18]. The latest guidelines of the
Surviving Sepsis Campaign recommend protocolized resuscita-
tion with intravenous ﬂuids and early empirical antibiotic
therapy [13], similarly to other meta-analyses [19,20], as mea-
sures to reduce mortality in severe sepsis.
An intriguing and novel ﬁnding from the current investi-
gation is the independent association of the presence of acute
graft rejection in the previous 6 months and mortality in
patients with BSI. At present, little is known about the rela-
tionship between sepsis and graft rejection. Nevertheless,
two recent retrospective analyses found that acute graft
rejection was an independent risk factor for urinary tract
infection in kidney recipients [21,22]. Moreover, in a pro-
spective study, acute graft rejection was associated with BSI
due to MDR GNB [6]. In histological terms, acute rejection is
observed as an inﬂammatory response of the host to the
transplanted organ, excluding the mechanisms that resulted in
the native graft disease [23]. Treatment modalities for acute
rejection generally entail augmentation of immunosuppressive
strategies. It might be speculated that the key is to ﬁnd the
dose of immunosuppressants that minimizes the risk of
rejection without causing a signiﬁcant increase in the risk of
infection.
Thrombocytopenia is frequently observed in critically ill
patients, and it has been associated with reduced survival
rates in general ICU populations with or without infections
[24,25]. Our study suggests that a platelet count of
<50 000 × 109/L is a risk factor for mortality in SOT re-
cipients with BSI. A highly signiﬁcant correlation between
platelet count and platelet adhesion to all leukocyte sub-
populations has been described. The exact mechanisms of this
interaction in sepsis are not clearly understood, although
there is increasing evidence that they play an important role
in the development of multiple organ failure and disseminated
intravascular coagulation [26]. A lower platelet count has
previously been identiﬁed as an unadjusted risk factor for
mortality in some retrospective studies in SOT recipients
with BSI [27,28].
In our study, kidney recipients with BSI had a lower
mortality rate than other organ recipients. This is probablyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectbecause kidney recipients are much more likely than the
other recipients to have a urinary source of infection, un-
dergo surgical manipulation, present with chronic local
inﬂammation, and require prosthetic devices [3,29]. More-
over, it is well known that BSI from a urinary source is usually
associated with a better outcome than BSI from other sour-
ces [30].
We did not ﬁnd an association between inadequate empirical
antibiotic therapy and poorer outcome. However, in our study,
the median onset of targeted antimicrobial therapy among
those patients initially receiving an inadequate empirical treat-
ment was <24 h. It can be speculated that a short delay in
receiving appropriate antimicrobial therapy does not neces-
sarily lead to an adverse outcome in SOT recipients. Moreover,
a recent study [31] showed that the mortality rate was lower
among SOT recipients than among non-transplant patients with
bacteraemia, suggesting that the immunosuppression associated
with transplantation may provide a survival advantage to
transplant recipients with sepsis through modulation of the
inﬂammatory response.
Our study has some limitations that should be noted. First, it
is a single-centre study, and our ﬁndings may be attributable to
institution-speciﬁc variables, and may not reﬂect the epidemi-
ology of different centres and/or geographical areas. Second, we
did not have information regarding previous patient coloniza-
tion and nutritional status. Finally, we analysed a heterogeneous
group of SOT recipients who may have had their own speciﬁc
risk factors for mortality.
In conclusion, this prospective study involving a large num-
ber of SOT recipients with BSI has shown that shock at pre-
sentation, previous acute graft rejection and a platelet count of
<50 000 × 109/L are independent risk factors for mortality in
SOT recipients with BSI. Kidney transplantation was associated
with a better prognosis. Further research is warranted to
improve preventive procedures, general measures and antibi-
otic therapy for BSI in this population of patients. Moreover,
the relationship between acute rejection and mortality should
be speciﬁcally examined in further studies.Transparency declarationThe authors of this manuscript have no conﬂicts of interest
related to the material presented.AcknowledgementsI. Oriol is the recipient of a APIF research grant from the
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